Xencor, Inc. (NASDAQ:XNCR) Holdings Lowered by DCF Advisers LLC

DCF Advisers LLC trimmed its position in Xencor, Inc. (NASDAQ:XNCR) by 3.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 203,167 shares of the biopharmaceutical company’s stock after selling 6,312 shares during the quarter. Xencor makes up approximately 2.3% of DCF Advisers LLC’s portfolio, making the stock its 14th largest position. DCF Advisers LLC’s holdings in Xencor were worth $4,669,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the company. KBC Group NV boosted its stake in Xencor by 63.5% in the 3rd quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 1,213 shares during the period. Thrivent Financial for Lutherans boosted its position in shares of Xencor by 127.3% in the third quarter. Thrivent Financial for Lutherans now owns 116,369 shares of the biopharmaceutical company’s stock worth $2,340,000 after buying an additional 65,180 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Xencor in the third quarter worth $362,000. Intech Investment Management LLC purchased a new position in shares of Xencor during the third quarter valued at $368,000. Finally, Charles Schwab Investment Management Inc. raised its position in Xencor by 7.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 626,988 shares of the biopharmaceutical company’s stock valued at $12,609,000 after buying an additional 40,788 shares during the period.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. StockNews.com lowered Xencor from a “hold” rating to a “sell” rating in a research report on Friday, March 14th. Piper Sandler upgraded shares of Xencor from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $20.00 to $30.00 in a report on Monday, December 2nd. Finally, Wells Fargo & Company dropped their price objective on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Xencor currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.38.

Xencor Trading Up 2.5 %

Xencor stock opened at $13.47 on Friday. The company’s fifty day simple moving average is $16.51 and its 200-day simple moving average is $20.30. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. Xencor, Inc. has a 12 month low of $12.54 and a 12 month high of $27.24. The stock has a market cap of $949.12 million, a P/E ratio of -4.21 and a beta of 0.75.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.19. The firm had revenue of $52.79 million during the quarter, compared to analysts’ expectations of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. As a group, sell-side analysts forecast that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.